JPS6069041A - Barium sulfate x-ray contrasting agent - Google Patents
Barium sulfate x-ray contrasting agentInfo
- Publication number
- JPS6069041A JPS6069041A JP58178925A JP17892583A JPS6069041A JP S6069041 A JPS6069041 A JP S6069041A JP 58178925 A JP58178925 A JP 58178925A JP 17892583 A JP17892583 A JP 17892583A JP S6069041 A JPS6069041 A JP S6069041A
- Authority
- JP
- Japan
- Prior art keywords
- barium sulfate
- contrast agent
- sol
- contrasting agent
- vanillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】 本発明はX線用硫酸バリウム造影剤に関する。[Detailed description of the invention] The present invention relates to a barium sulfate contrast agent for X-rays.
一般にX線用硫酸バリウム造影剤は、硫酸バリウム濃度
が高く、胃内凝集を起こさず、流動性、拡散性、付着性
、親和性等に優れ、服用し易いこと等の諸条件を具備す
ることが要求されている。In general, barium sulfate contrast agents for X-rays have the following conditions: high concentration of barium sulfate, no aggregation in the stomach, excellent fluidity, diffusivity, adhesion, affinity, etc., and ease of administration. is required.
従来よりこの種硫酸バリウム造影剤として種々のものが
知られているが、上記諸条件を充分に満足し得るものは
未だ見当たらない。特に最近の診断技術の急速な進歩に
より微細病変像の正確な描写ができる造影剤の開発が要
求されて来ている。Various types of barium sulfate contrast agents have been known, but none that fully satisfies the above conditions has yet been found. In particular, with recent rapid advances in diagnostic technology, there has been a demand for the development of contrast agents that can accurately depict images of minute lesions.
一般的に硫酸バリウム濃度が高い捏持られるX線写真像
のコントラストが増大される即ち造影効果の改良を計り
得ると考えられるが、その反面上記濃度を高くすると、
m膨剤自体の粘度が増大して服用し難くなると共に、付
着性、流動性等の諸性質も低下する傾向となり、結局の
ところ微細病変像の正確な描写が困難になっている。即
ち、硫酸バリウム濃度の高い従来の造影剤では、(1)
経時的に不安定であるため、胃酸との接触混合により
時間の経過と共に次第に流動性がなくなり硫酸バリウム
粒子間凝集が進み厚い層となり、それが固定化されて動
かなくなる現象、所謂ペタツキ感現象が生じたり、(2
)胃壁の内部に造影剤が均一に付着せず、造影剤が付着
し過ぎるところと殆んど付着しないところが生ずる所謂
付着むらを生じたり、付着むらの程度が激しい場合には
硫酸バリウム自身の凝集群を発生し粘土化し流動性がな
くなる等の難点がある。従ってこのような付着性、流動
性等の難点を有する高濃度の硫酸バリウム造膨剤を使用
した場合、胃壁の微細病変部等の撮影すべき部位へ造影
剤が侵入すること及び該部位に造影剤が均一に付着する
ことが困難であるところから、常に安定して正確な微細
病変像を得ることが困難になっているのである。Generally, it is thought that a high concentration of barium sulfate increases the contrast of the mixed X-ray image, that is, improves the contrast effect, but on the other hand, when the concentration is increased,
The viscosity of the m-swelling agent itself increases, making it difficult to take, and various properties such as adhesion and fluidity tend to decrease, ultimately making it difficult to accurately depict images of minute lesions. That is, in conventional contrast agents with a high concentration of barium sulfate, (1)
Because it is unstable over time, it gradually loses its fluidity over time due to contact and mixing with stomach acid, and aggregation between barium sulfate particles progresses to form a thick layer, which becomes fixed and does not move, a so-called sticky feeling phenomenon. (2
) The contrast medium does not adhere uniformly to the inside of the stomach wall, resulting in so-called uneven adhesion, where there are areas where too much contrast agent adheres and areas where it barely adheres, or if the degree of uneven adhesion is severe, barium sulfate itself may aggregate. There are disadvantages such as forming clumps, turning into clay, and losing fluidity. Therefore, when using a high-concentration barium sulfate swelling agent that has problems such as adhesion and fluidity, the contrast agent may enter the area to be imaged, such as minute lesions on the gastric wall, and the contrast agent may not be applied to the area. Since it is difficult for the agent to adhere uniformly, it is difficult to always obtain stable and accurate images of minute lesions.
本発明者らは、斯かる現状に鑑み上記難点を有さない高
濃度の硫酸バリウム造影剤を開発すべく鋭意研究を重ね
た結果、下記組成の造影剤が本発明の所期の目的を達成
し得ることを見い出した。In view of the current situation, the present inventors have conducted intensive research to develop a high-concentration barium sulfate contrast agent that does not have the above-mentioned drawbacks, and as a result, a contrast agent with the following composition has achieved the intended purpose of the present invention. I found out what I can do.
本発明は斯かる知見に基づき完成されたものである。The present invention was completed based on this knowledge.
即ち本発明は、バニリン酸及び/又はバニリンとトラガ
ントガム及び/又はその処理物とを含有することを特徴
とするX線用硫酸バリウム造影剤に係る。That is, the present invention relates to a barium sulfate contrast agent for X-rays characterized by containing vanillic acid and/or vanillin and gum tragacanth and/or a processed product thereof.
本発明の硫酸バリウム造影剤の最大の特徴とする所は、
硫酸バリウム濃度が高く、しかも低粘度であって服用が
容易であり且つ優れた付着性や流動性を有することであ
る。また本発明の硫酸バリウム造影剤は、拡散性、親和
性、再分散性等に優れる等の利点を有する。それ放水発
明の硫酸バリウム造影剤は、この種造影剤に要求される
諸条件を全て具備するものであり、理想的なX線用硫酸
バリウム造影剤である。さらに説明を加えれば、本発明
の造影剤は、服用時は牛乳のような低粘度ゾルであるた
めに服用が極めて容易であり、また特に経時的な流動性
に優れているため、胃壁微細病変部(凹凸部)等の撮影
すべき部位への侵入は容易である。そして一旦侵入が完
了すれば、胃壁、胃小区との親和性がすぐれ胃壁微細病
変部等の撮影すべき部位に該造影剤が強力に付着される
。しかも胃酸との接触混合時も時開の鴫戸によっても全
く悪影響を受けない。本発明の硫酸バリウム造影剤は、
付着性に優れたものであり、従来の高濃度硫酸バリウム
造影剤のような付着むらを生ずることはない。また本発
明の硫酸バリウム造影剤は、ペタツキ感現象を生ずるも
のではない。従って該造影剤を消化inの診断に用いる
場合、極めて服用し易く、また消化管壁の細部まで硫酸
バリウム粒子を付着させ得、該消化管壁の状態を極めて
正確に造影させる効果を発揮する。更に本発明のX線用
硫酸バリウム造影剤は、経時的に極めて安定である。特
に懸濁状形態を有する本発明造影剤を長期保存した場合
、懸濁粒子は下I一部に沈降するが、軽い衝撃を与える
ことにより、例えば振盪することにより、製造時の状態
に復元でき、同等支障を生ずることなく造影剤として使
用し得る。The most important features of the barium sulfate contrast agent of the present invention are:
It has a high barium sulfate concentration and low viscosity, making it easy to take and having excellent adhesion and fluidity. Furthermore, the barium sulfate contrast agent of the present invention has advantages such as excellent diffusibility, affinity, redispersibility, and the like. The barium sulfate contrast agent of the water spray invention satisfies all the conditions required for this type of contrast agent, and is an ideal barium sulfate contrast agent for X-rays. To explain further, the contrast agent of the present invention is extremely easy to take as it is a low viscosity sol like milk, and has particularly excellent fluidity over time, so it can be used to treat minute lesions on the gastric wall. It is easy to penetrate into areas to be imaged, such as irregularities (uneven areas). Once the penetration is completed, the contrast agent has excellent affinity with the gastric wall and gastric subdivisions, and the contrast agent strongly adheres to the site to be imaged, such as a minute lesion on the gastric wall. What's more, when it comes into contact with stomach acid, it is not adversely affected at all by Shikido. The barium sulfate contrast agent of the present invention is
It has excellent adhesion and does not cause uneven adhesion unlike conventional high-concentration barium sulfate contrast agents. Further, the barium sulfate contrast agent of the present invention does not cause a flat feeling phenomenon. Therefore, when the contrast agent is used for diagnosis of indigestion, it is extremely easy to take, and the barium sulfate particles can be attached to even the smallest details of the wall of the gastrointestinal tract, resulting in an extremely accurate contrast imaging of the condition of the wall of the gastrointestinal tract. Furthermore, the barium sulfate contrast agent for X-rays of the present invention is extremely stable over time. In particular, when the contrast agent of the present invention in a suspended form is stored for a long period of time, the suspended particles settle in a part of the lower part, but by applying a light impact, for example, by shaking, it is possible to restore the state to the state at the time of manufacture. , it can be used as a contrast agent without causing any problems.
本発明のX線用硫酸バリウム造影剤は、バニリン酸及び
/又はバニリン(以下「A成分」という)を含有するこ
とを必須とする。A成分の配合量としては特に限定がな
く広い範囲内で適宜選択すればよいが、通常硫酸バリウ
ム100重嵐部(以下単に「部」と記す)に対し固型分
重量として約0.004〜4部、好ましくは約0.1〜
2部、最も好ましくは約0.125〜1部とするのがよ
い。The barium sulfate contrast agent for X-rays of the present invention essentially contains vanillic acid and/or vanillin (hereinafter referred to as "component A"). The amount of component A to be blended is not particularly limited and may be appropriately selected within a wide range, but it is usually about 0.004 to 0.004 to 100 parts by weight (hereinafter simply referred to as "parts") of solid content per 100 parts by weight of barium sulfate. 4 parts, preferably from about 0.1 to
2 parts, most preferably about 0.125 to 1 part.
さらにまた本発明のX線用硫酸バリウム造影剤は、トラ
ガントガムもしくはその処理物(以下「B成分」という
)をも含有することを必須とする。トラガントガムの処
理物としては、従来公知のものを広く使用でき、例えば
トラガントガムに物理的手段・化学的手段または生物学
的手段或いはこれらを適宜組み合わせた手段を施して得
られたものもしくはこれから単離したものであって、且
つこれを1wt%濃度の水溶液としたときの粘度[80
℃、 80 rpm にてローター凪2または8で測定
を行なう、以下同じ]が約1〜500cpの範囲内にあ
るものをいずれも使用できる。これらのうちで前記粘度
が約1〜200 cpの範囲内にあるものを用いるのが
好ましい。トラガントガム処理物として具体的には例え
ばトラガントガムの水抽出物を挙げることができる。ト
ラガントガムの水抽出物はトラガントガムを常法に従い
水で抽出することにより製造できる。Furthermore, the barium sulfate contrast agent for X-rays of the present invention must also contain gum tragacanth or a processed product thereof (hereinafter referred to as "component B"). As the processed product of gum tragacanth, a wide range of conventionally known products can be used, such as those obtained by subjecting gum tragacanth to physical means, chemical means, biological means, or a suitable combination of these, or those isolated from this. and when it is made into an aqueous solution with a concentration of 1 wt%, the viscosity [80
C., 80 rpm, rotor calm 2 or 8, the same hereinafter] is within the range of about 1 to 500 cp can be used. Among these, it is preferable to use those having a viscosity within the range of about 1 to 200 cp. A specific example of the processed product of gum tragacanth is an aqueous extract of gum tragacanth. A water extract of gum tragacanth can be produced by extracting gum tragacanth with water according to a conventional method.
本発明のX線用硫酸バリウム造影剤は、基本的には硫酸
バリウム、A成分及びB成分の混合物から成る粉末状形
態又はこれを水に懸濁した懸濁状態を有する。該造影剤
はまた更に公知の各種添加剤例えば湿潤剤、消泡剤、甘
味剤、香料又は防腐剤等を含有していてもよい。懸濁状
形態を有する本発明造影剤は、例えば上記硫酸バリウム
、A成分及びB成分を、必要に応じ添加剤と共に、適当
量の水、通常硫酸バリウム濃度が50〜200W/V%
、好ましくは100〜200 W/V%となる訛の水に
添加し混合撹拌することにより調製される。これはその
まま造影剤として服用できる。The barium sulfate contrast agent for X-rays of the present invention basically has a powder form consisting of a mixture of barium sulfate, component A, and component B, or a suspension state in which it is suspended in water. The contrast agent may further contain various known additives such as wetting agents, antifoaming agents, sweetening agents, flavoring agents, or preservatives. The contrast agent of the present invention in a suspended form can be prepared by combining, for example, the above-mentioned barium sulfate, component A, and component B, together with additives if necessary, an appropriate amount of water, and a barium sulfate concentration of usually 50 to 200 W/V%.
, preferably 100 to 200 W/V%, is added to water and mixed and stirred. This can be taken directly as a contrast agent.
また粉末状形態を有する本発明造影剤は、硫酸バリウム
、A成分及びB成分を単に粉体混合しても製造でき、ま
た例えば上記で調製した懸濁液を噴震乾燥法、湿式顆粒
法等により乾燥することによっても製造できる。これは
保存、輸送等に便利であり、造影剤としての使用に当っ
ては、水を加えて撹拌することにより容易に服用可能な
液状形態に復元できる。加えられる水量は通常50〜2
00W/V%硫酸バリウムゾル、好ましくは100〜2
00 W/V%硫酸バリウムゾルが形成され得る量とす
ればよい。The contrast agent of the present invention having a powder form can also be produced by simply mixing barium sulfate, component A, and component B in powder form, or, for example, by mixing the suspension prepared above using a spray drying method, a wet granulation method, etc. It can also be produced by drying. This is convenient for storage, transportation, etc., and when used as a contrast agent, it can be easily restored to a liquid form that can be taken by adding water and stirring. The amount of water added is usually 50-2
00W/V% barium sulfate sol, preferably 100-2
The amount may be such that a 0.00 W/V% barium sulfate sol can be formed.
以下本発明を更に詳しく説明するため、トラガントガム
の水抽出物の製造法を参考例として挙げ、また本発明造
影剤の処方例及び試験例を挙げる。In order to explain the present invention in more detail, a method for producing an aqueous extract of gum tragacanth will be cited as a reference example, and formulation examples and test examples of the contrast agent of the present invention will be listed below.
参考例
予め調製したトラガントガム2%水性懸濁液を一夜放置
後、遠心分離により懸濁物質を除去し、上澄液を取り、
これにそのl/2重量倍のエタノールを加え析出物質を
再び遠心分離により分離する。分離された固型物を乾燥
粉末化して、トラガントガムの水抽出物粉末を80%の
収率で得る。Reference Example After leaving a 2% aqueous suspension of gum tragacanth prepared in advance overnight, the suspended matter was removed by centrifugation, and the supernatant was taken.
To this is added 1/2 times the weight of ethanol, and the precipitated material is again separated by centrifugation. The separated solids are dried and powdered to obtain gum tragacanth water extract powder with a yield of 80%.
これは 〔α〕25=−+−s5°(C=0.5%、0
.2N−NaOH水溶液)を示す。一方懸濁物質は〔α
〕25=+222°CC= 0.5%、0.2N−Na
OH水溶液)を示した。粘度:15cp
処方例1
硫酸バリウム480kjl、砂糖25kN、上記参考例
で得られる水仙出物乾燥粉末1.920kf 及びバニ
リン800gを精製水1201に添加し、混合機で充分
撹拌して200 W/V%硫酸バリウムゾルを得る。又
上記処方で得られるゾルを噴甥乾燥法で乾燥後粉末化し
て、粉末状の硫酸バリウム造影剤を得る。This is [α]25=-+-s5°(C=0.5%, 0
.. 2N-NaOH aqueous solution). On the other hand, suspended solids are [α
]25=+222°CC=0.5%, 0.2N-Na
OH aqueous solution). Viscosity: 15 cp Formulation Example 1 480 kjl of barium sulfate, 25 kN of sugar, 1.920 kf of dried daffodil extract powder obtained in the above reference example, and 800 g of vanillin were added to 1201 purified water and thoroughly stirred with a mixer to give 200 W/V%. Obtain barium sulfate sol. Further, the sol obtained with the above formulation is dried by a blow drying method and then pulverized to obtain a powdered barium sulfate contrast agent.
処方例2
硫酸バリウム480kN、砂糖25kl、上記参考例で
得られる水抽出物乾燥粉末1.920kg、バニリン酸
5ooy及び精製水2oo11を混合機にて充分撹拌し
て150 W/V %硫酸バリウムゾルを得る。Formulation Example 2 480kN of barium sulfate, 25kl of sugar, 1.920kg of the water extract dry powder obtained in the above reference example, 5ooy of vanillic acid and 2oo11 of purified water are sufficiently stirred in a mixer to obtain a 150 W/V% barium sulfate sol. .
処方例8
硫酸バリウム480kN、砂糖25に11.)ラガント
ガム5.56kf、バニリン200y、グリセリン1.
2kf、ソルビン酸0.4kl、シリコーン樹脂4.O
f及び精製水8601を加え混合機で充分撹拌してi
o OW/V %硫酸バリウムゾルを得る。Prescription example 8 Barium sulfate 480kN, sugar 25% and 11%. ) Lagant gum 5.56kf, vanillin 200y, glycerin 1.
2kf, sorbic acid 0.4kl, silicone resin 4. O
Add f and purified water 8601 and stir thoroughly with a mixer.
o Obtain OW/V% barium sulfate sol.
処方例4
硫酸バリウム480 kl’、砂糖25kf、)ラガン
トガム5.5kF 及びバニリン酸25Ofを精製水2
621に添加し混合機で充分撹拌して120W/V %
硫酸バリウムゾルを得る。Formulation example 4 480 kl of barium sulfate, 25 kf of sugar, 5.5 kF of gum lagant, and 25 Of vanillic acid in purified water 2
Add to 621 and stir thoroughly with a mixer to make 120W/V%.
Obtain barium sulfate sol.
処方例5
硫酸バリウA 480 kl、砂糖25kN、上記参考
例で得られる水仙出物乾燥粉末1.920kF 及びバ
ニリン酸8009を精製水120/に添加し混合機で充
分撹拌して200 W/V %硫酸バリウムゾルを得る
。Formulation Example 5 480 kl of Barium sulfate A, 25 kN of sugar, 1.920 kF of dried powder of daffodil extract obtained in the above reference example, and vanillic acid 8009 were added to 120 kg of purified water and thoroughly stirred with a mixer to yield 200 W/V%. Obtain barium sulfate sol.
処方例6
硫酸バリウム480kf、砂糖25kN、上記参考例で
得られる水抽出物乾燥粉末1.920kF。Formulation Example 6 Barium sulfate 480kF, sugar 25kN, water extract dry powder obtained in the above reference example 1.920kF.
バニリン800f及び精製水2001を混合機にて充分
撹拌して150 W/V%硫酸バリウムゾルを得る。Vanillin 800f and purified water 2001 are sufficiently stirred in a mixer to obtain a 150 W/V% barium sulfate sol.
処方例7
硫酸バリウム480に&、砂糖25kl、水仙出物乾燥
粉末1.920kg 及びバニリン酸aooF/を精製
水1201に添加し混合機で充分撹拌して200 W/
V%硫酸バリウムゾルを得る。Formulation Example 7 Add barium sulfate 480, sugar 25kl, daffodil extract dry powder 1.920kg, and vanillic acid aooF/1201 to purified water, stir thoroughly with a mixer to make 200 W/
A V% barium sulfate sol is obtained.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸濁剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
処方例8
硫酸バリウム480 kg、砂糖25 kg、水抽出物
乾燥粉末1.920kF 及びバニリン酸800gを精
製水1701に添加し混合機で充分撹拌して170 W
/V%硫酸バリウムゾルを得る。Formulation Example 8 480 kg of barium sulfate, 25 kg of sugar, 1.920 kF of water extract dry powder, and 800 g of vanillic acid were added to 1701 purified water and thoroughly stirred with a mixer to produce 170 W
/V% barium sulfate sol is obtained.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸濁剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
処方例9
硫酸バリウム480に&、砂糖25kf、水抽出物乾燥
粉末1.920kf 及びバニリン800yを精製水2
001に添加し混合機で充分撹拌して150 W/V%
硫酸バリウムゾルを得る。Formulation Example 9 Barium sulfate 480 & sugar 25kf, water extract dry powder 1.920kf and vanillin 800y purified water 2
Add to 001 and stir thoroughly with a mixer to make 150 W/V%.
Obtain barium sulfate sol.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸−剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
処方例10
硫酸バリウム480 kl、砂糖25 kg、水抽出物
乾燥粉末1.920kN 及びバニリン800gを精製
水2801に添加し混合機で充分撹拌して140 W/
V%硫酸バリウムゾルを得る。Formulation Example 10 480 kl of barium sulfate, 25 kg of sugar, 1.920 kN of water extract dry powder, and 800 g of vanillin were added to 2801 g of purified water and thoroughly stirred with a mixer to produce 140 W/
A V% barium sulfate sol is obtained.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸濁剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
処方例11−
硫酸バリウム480に&、砂糖25kg、水仙出物乾燥
粉末1.920kf、及びバニリン酸800y ヲm製
水2601に添加し混合機で充分撹拌して180 W/
V%硫酸バリウムゾルを得る。Formulation Example 11 - Add 480 barium sulfate, 25 kg of sugar, 1.920 kf of dried daffodil extract powder, and 800 y of vanillic acid to 2601 wom water and stir thoroughly with a mixer to make 180 W/
A V% barium sulfate sol is obtained.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸澗剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension agent before use.
処方例12
硫酸バリウム480kf、砂糖25kf、水仙出物乾燥
粉末5.5ky、及びバニリン250yを精製水284
1に添加し混合機で充分撹拌して120W/V%硫酸バ
リウムゾルを得る。Formulation Example 12 480kf of barium sulfate, 25kf of sugar, 5.5ky of dried narcissus extract powder, and 250y of vanillin in 284ml of purified water.
1 and thoroughly stirred with a mixer to obtain a 120 W/V% barium sulfate sol.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸濁剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
処方例13
硫酸バリウム480 kN、砂糖25 kF、水仙出物
乾燥粉末5.55kjl、バニリン20 Of、グリセ
リン1.2に&、ソルビン酸0.4kf、及びシリコー
ン樹脂4.Ofを精製水3601に添加し混合機で充分
撹拌して100 W/V %硫酸バリウムゾルを得る。Formulation Example 13 Barium sulfate 480 kN, sugar 25 kF, daffodil extract dry powder 5.55 kjl, vanillin 20 Of, glycerin 1.2 &, sorbic acid 0.4 kf, and silicone resin 4. Of is added to purified water 3601 and thoroughly stirred with a mixer to obtain a 100 W/V% barium sulfate sol.
また上記処方で得られるゾルを通常の乾燥方法、例えば
噴霧乾燥法などで乾燥微粉化して、用時懸濁剤としての
本発明化合物を得る。Further, the sol obtained with the above formulation is dried and pulverized by a conventional drying method, such as a spray drying method, to obtain the compound of the present invention as a suspension before use.
試験例1
種々の硫酸バリウムゾル200 mllを80°Cに維
持しつつlN−HCl水溶液を添加する。エメスターラ
AS−2(東洋科学産業波)を用い、回転数10 Or
pm で約1分間撹拌後、芝浦システム製VS−AI型
ビスメトロン単一円筒型回転粘度計を用いて粘度を測定
する。IN′−HCl 水溶液をさらに添加し粘度を測
定するという操作を繰返し行ない、lN−HCl水溶液
添加量と粘度との関係をpH依存粘度曲線としてめる。Test Example 1 1N-HCl aqueous solution is added to 200 ml of various barium sulfate sols while maintaining the temperature at 80°C. Using Emestara AS-2 (Toyo Kagaku Sangyo Wave), rotation speed 10 Or
After stirring for about 1 minute at pm, the viscosity is measured using a VS-AI model Vismetron single cylinder rotational viscometer manufactured by Shibaura System. The operation of adding more IN'-HCl aqueous solution and measuring the viscosity is repeated, and the relationship between the amount of IN'-HCl aqueous solution added and the viscosity is determined as a pH-dependent viscosity curve.
その結果を第1図に示す。第1図において→−← は処
方例3の硫酸バリウムゾルについてのグラフであり、→
−(ト)は処方例4の硫酸バリウムゾルについてのグラ
フであり、(H)はバリトゲンゾル(伏見製薬所製)に
ついてのグラフであり、咄−すは流動X −5oll
20 (扶桑薬品製)についてのグラフであり、→。1
はバリトップ120(堺化学製)についてのグラフで
ある。第1図から本発明の硫酸バリウム造影剤は、HC
#の添加量や時間の経過に関係なく安定なゾル粘度の移
行を示すことが明らかである。The results are shown in FIG. In Figure 1, →-← is a graph for the barium sulfate sol of Prescription Example 3, and →
-(G) is a graph for barium sulfate sol of Prescription Example 4, (H) is a graph for Baritogen sol (manufactured by Fushimi Pharmaceutical Co., Ltd.),
20 (manufactured by Fuso Pharmaceutical), →. 1
is a graph for Varitop 120 (manufactured by Sakai Chemical). From FIG. 1, the barium sulfate contrast agent of the present invention is HC
It is clear that the sol viscosity changes stably regardless of the amount of # added or the passage of time.
試験例2
シャーレ中ゼラチン膜により人工胃壁を作成し、局方第
一液と各種硫酸バリウムゾルとを5:1の割合で混合し
、経時的に混合直後、10分後、20分後、80分後及
び1時間後者々静かに左右前後にローリングする(同一
条件)ことにより、流動性、凝集性、付着、性、親和性
、均−性等を観察する。Test Example 2 An artificial stomach wall was created using a gelatin film in a petri dish, and the first pharmacopoeia liquid and various barium sulfate sols were mixed at a ratio of 5:1, and the walls were heated over time immediately after mixing, 10 minutes later, 20 minutes later, and 80 minutes later. Afterwards, the fluidity, cohesiveness, adhesion, properties, affinity, homogeneity, etc. are observed by gently rolling the mixture back and forth from side to side for 1 hour (same conditions).
a)外観
b)ソフテックXEMBW(SOFTEX Co、Lt
d、)使用によるX線写真
得られた結果を第1表に示す。第1表において、十十+
十干印は特にずばらしい、十++十印は良好、十+十印
はやや良好、+十印は使用に耐え得る、士印は使用不可
を示すものである。尚比較対照例1はバリトゲンゾルを
、比較対照例2はバ’J)ツブ120を、比較対照例8
は流動X−5oA’120を、比較対照例4は硫酸バリ
ウム480ky、砂糖25 kl 及び参考例で得たト
ラガントガムの水抽出物乾燥粉末1.920kg を精
製水1201に添加し混合機で充分撹拌して得られる2
00 W/V%硫酸バリウムゾルをそれぞれ使用した
ものである。a) Appearance b) SOFTEX XEMBW (SOFTEX Co, Lt.
d.) Radiographs obtained using X-rays The results obtained are shown in Table 1. In Table 1, 10+
Juhan-in is particularly excellent, 10++ 10-in is good, 10 + 10-in is somewhat good, + 10-in is usable, and Shiin is unusable. Comparative Control Example 1 uses Baritogen Sol, Comparative Control Example 2 uses Ba'J) Tubu 120, and Comparative Control Example 8
For Comparative Example 4, 480 ky of barium sulfate, 25 kl of sugar, and 1.920 kg of the dried powder of water extract of gum tragacanth obtained in Reference Example were added to 1201 purified water and thoroughly stirred with a mixer. 2 obtained by
00 W/V% barium sulfate sol was used in each case.
第1表 第 1 表 (続き)Table 1 Table 1 (continued)
第1図は各種硫酸バリウムゾルのpH依存粘度曲線を示
すグラフである。
(以上)
代理人 弁理士 三 枝 英 二FIG. 1 is a graph showing pH-dependent viscosity curves of various barium sulfate sols. (Above) Agent: Eiji Saegusa, Patent Attorney
Claims (1)
び/又はその処理物とを含有することを特徴とするX線
用硫酸バリウム造影剤。(2) A barium sulfate contrast agent for X-rays, characterized by containing vanillic acid and/or vanillin and gum tragacanth and/or a processed product thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58178925A JPS6069041A (en) | 1983-09-26 | 1983-09-26 | Barium sulfate x-ray contrasting agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58178925A JPS6069041A (en) | 1983-09-26 | 1983-09-26 | Barium sulfate x-ray contrasting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6069041A true JPS6069041A (en) | 1985-04-19 |
Family
ID=16057039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58178925A Pending JPS6069041A (en) | 1983-09-26 | 1983-09-26 | Barium sulfate x-ray contrasting agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6069041A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0285217A (en) * | 1988-09-22 | 1990-03-26 | Ota Seiyaku Kk | Barium sulfate contrast medium for x ray examination of large intestine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163827A (en) * | 1978-06-13 | 1979-12-26 | Otsuka Pharma Co Ltd | Xxray barium sulphate contrast medium |
| JPS55127322A (en) * | 1979-03-26 | 1980-10-02 | Otsuka Pharmaceut Factory Inc | Barium sulfate contrast medium for x-ray radiography |
| SU797687A1 (en) * | 1978-07-14 | 1981-01-23 | Московский Областной Ордена Трудовогокрасного Знамени Научно-Исследовательскийклинический Институт Им. M.Ф.Владимирского | Agent for x-ray and microangiography examination |
-
1983
- 1983-09-26 JP JP58178925A patent/JPS6069041A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163827A (en) * | 1978-06-13 | 1979-12-26 | Otsuka Pharma Co Ltd | Xxray barium sulphate contrast medium |
| SU797687A1 (en) * | 1978-07-14 | 1981-01-23 | Московский Областной Ордена Трудовогокрасного Знамени Научно-Исследовательскийклинический Институт Им. M.Ф.Владимирского | Agent for x-ray and microangiography examination |
| JPS55127322A (en) * | 1979-03-26 | 1980-10-02 | Otsuka Pharmaceut Factory Inc | Barium sulfate contrast medium for x-ray radiography |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0285217A (en) * | 1988-09-22 | 1990-03-26 | Ota Seiyaku Kk | Barium sulfate contrast medium for x ray examination of large intestine |
| US5160724A (en) * | 1988-09-22 | 1992-11-03 | Ohta Seiyaku Kabushiki Kaisha | Barium sulfate contrast medium for x-ray examination of the large intestine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0662320B1 (en) | Dry gel composition | |
| KR101330096B1 (en) | Process for the manufacture of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate | |
| WO1988006457A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
| US4150110A (en) | Coated granules of polyacrylic alkali metal salts and method of producing same | |
| HU195629B (en) | Process for production of barium-sulphate with high liquidity and viscosity serving as shadow-giving component of x-rays contrast material and x-rays contrast material containing barium sulphate resulted from this process | |
| JPS58183607A (en) | Dental cement | |
| JP2735559B2 (en) | Suspension | |
| US2487600A (en) | Aqueous thixotropic gel composition | |
| JPH01311024A (en) | Drug preparation having controlled acting substance release properties containing azelastine and production thereof | |
| US4020152A (en) | Barium titanate and barium zirconate in radiological contrast products | |
| JPS6069041A (en) | Barium sulfate x-ray contrasting agent | |
| Embring et al. | Barium contrast agents | |
| JP3253948B2 (en) | Capsule | |
| JP3068343B2 (en) | Composition for diagnosing swallowing function | |
| HU203477B (en) | Process for producing antiflatulant pharmaceutical compositions containing activated poly-dimethyl-siloxane in form of solide dispersion | |
| JPH05255092A (en) | Composition for intestinal canal lavage | |
| JP3717007B2 (en) | Novel barium powder formulation, ultra-high concentration barium suspension for upper gastrointestinal tract imaging using the same, and production method thereof | |
| JPS6019884B2 (en) | Film-type pack agent | |
| US5563258A (en) | Sucralfate aqueous suspension and its method of preparation | |
| EP0143576A1 (en) | An antacid composition and a process for the preparation thereof | |
| CN115721611A (en) | Vonola fumarate dry suspension and preparation method thereof | |
| RU2118172C1 (en) | Radio-opaque agent for diagnosis of gastroenteric tract pathology | |
| JPS59148718A (en) | Ubidecarenone composition | |
| JP2833309B2 (en) | Barium sulfate contrast agent for CT | |
| JPH0530805B2 (en) |